EP429: Following the Dollar Through Pharmacy Acronyms Like WAC, AWP, and NADAC, With Luke Slindee, PharmD
March 07, 2024
429
38:20

EP429: Following the Dollar Through Pharmacy Acronyms Like WAC, AWP, and NADAC, With Luke Slindee, PharmD

In this healthcare podcast we’re talking about pharmacy acronyms or terms like AWP and WAC, and, not really an acronym, but we’ll also talk pharmacy list prices, rebates, discounts. We also have NADAC, but that’s slightly off to the side for reasons we’ll get to in a sec.

For a full transcript of this episode, click here.

Most of these acronyms refer to a number with a dollar sign in front of it, and it’s hell on wheels to figure out if and/or to what extent that number reflects what is going on in the real world, especially if you are a patient or a plan sponsor and all you see is the list price that Pharma puts out on one side of the storyboard, and then what the patient pays or (if you’re lucky) what the plan pays for the drug on the way other side of the whole chain of events. What’s a black box a lot of times for patients and plan sponsors is what goes on in the middle, wherein many middle people get their mitts on the transaction.

Love the show? Please consider signing up for our weekly newsletter. We'll send you an article covering the latest episode with show notes, mentioned links and a transcribed intro. Join the RHV Tribe.

Real quick here, let’s run through the Mister Rogers’ neighborhood of all of these middle people right now; and we’re gonna do this really briefly. Most of you are already going to know most of this, but I just want to remind you so that when my guest today, Luke Slindee, and I kick into the conversation about the acronyms and the terms and we try to follow the dollar … yeah, you can put a name to a face.

Alright, so first we have pharma manufacturers. The pharma manufacturer—and this is largely gonna be true whether it’s a branded drug or a generic pharma manufacturer—but the manufacturer sets a list price. This list price is gonna be called an AWP or a WAC price, and we’re gonna get into the differences and what those terms actually mean in the show that follows.

But Pharma decides their price point. They go to wholesalers with that price. Wholesalers say they want a discount to purchase the product. Some kind of rebate or discount is negotiated. Now the wholesalers have the drug, and they get calls from pharmacies. Pharmacies have patients who have scripts for that, so the pharmacies need to buy the drug. What price does the pharmacy now pay the wholesaler for the drug?

Short answer: It’s nuts. It’s nuts how the wholesalers decide what to charge the pharmacies for the drug. We talk about that in the interview that follows, but suffice to say that now we have the list price turning into whatever price the pharmacies wound up paying to get the drug from the wholesalers for. Any way you cut it, the wholesalers are making some money.

Okay … now we get to the part where we’re figuring out how much the patient or the plan sponsor will pay to pick up that drug that started at the pharma manufacturers and went to the wholesalers and now is at the pharmacy. How much are the patients gonna pay? How much are the plan sponsors gonna pay?

If you spend any time in the real world (not the drug supply chain world), what you’d expect to happen next is that the patient would go into the pharmacy and the pharmacist would charge a markup and/or a dispensing fee on the price that they bought the drug from the wholesaler for. That’d be normal. And this can be the case when patients pay cash. Listen to the show with Mark Cuban (EP418, along with Ferrin Williams, PharmD, MBA), who started a pharmacy called Cost Plus Drugs. Get it? Their prices are cost plus. You have had other pharmacies for years doing similar things, like Blueberry in Pittsburgh. They get the drug. They buy it from a wholesaler or etc. But they buy the drug for some price, and then they sell it to their customers (ie, patients) at their cost plus.

But most of the time in pharmacy supply chain world, things don’t work that way because many patients have insurance. When a patient walks into the pharmacy, someone has to figure out how much the patient owes and how much their insurance will cover, right? So, enter PBMs (pharmacy benefit managers). They originally started out doing this math (ie, adjudicating claims), figuring out what the out-of-pocket will be for the patient and then what the insurance will cover. Then drugs started to get really expensive and a few other developments, and then, all of a sudden, we have PBMs negotiating with Pharma for how much of a rebate the PBM is going to demand for the PBM to put the manufacturer drug on formulary. The PBM also is determining how much they will pay the pharmacy for said drug on behalf of plan sponsors, in addition to doing the math for how much the patient will pay.

So, let me say that again because it kind of begs a “what now?” with eyebrows sky-high as the appropriate response to what I just said, especially if you think through the ramifications here, ramifications which I discuss at length with Vinay Patel (EP241); Benjamin Jolley, PharmD (EP422); Scott Haas (EP365); Paul Holmes (EP397); and others.

So, again, the PBM is not just adjudicating claims. They are also negotiating rebates from Pharma so plan sponsors do not have to pay the full amount that the wholesalers paid Pharma and that the pharmacies paid the wholesalers, which maybe is a lot of money. The PBMs are like, “Hey, Pharma. You need to give me a piece of your action because we, the PBM, have big market power. I serve 100 million patients or something. So, if you want access to my 100 million lives, you gotta shell it out. You gotta shell me out some rebates.”

So, fine, Pharma gives the PBM some amount of money in the form of a rebate. And it has to work that way, if you think about it, because the drug was originally sold to the wholesaler. You see what I’m saying? So, the pharma company has to give the PBMs a separate rebate amount. This is in addition to how much the PBM told the plan sponsor the plan sponsor owes for the drug, which is also paid to the PBM. But now, PBM is also still in charge of adjudicating the claim. So, they’re telling the pharmacy how much to charge the patient. Somehow or another also, the PBM also got itself in charge of deciding how much money the pharmacy itself would be reimbursed by that PBM.

In the rest of the world, the pharmacy might tell the PBM, “Hey, this is the price.” But not in pharmacy supply chain world. In pharmacy supply chain world, the PBM tells the pharmacy how much it’s gonna pay. The end.

And this, my friends, is how so often pharmacies get themselves in the pickle of having to pay the wholesaler one price to get the drug while they get reimbursed a totally different price to dispense the drug. And because independents have very little negotiating leverage on actually either side of that equation, they so very often buy high and sell low. Please listen to the shows with Benjamin Jolley (EP422) and Vinay Patel (EP241), where we get into this in a lot of detail.

But I just want to emphasize this point: All of that whole drug supply chain I just went through, where the manufacturer sells to the wholesaler who sells to the pharmacy and the PBM pays the pharmacy and the patient is paying something and the plan sponsor is paying something—many of the middleman transactions in there happen under the cover of darkness a lot of times. If I’m a plan sponsor, do I have any idea how much the PBM paid the pharmacy for any particular drug? Unless you’re good at looking at the NADAC numbers (more on this coming up), no. I do not have any idea what a fair price for that drug actually is and how much people are making on the back of that drug as it goes through the supply chain.

And this, my friends, is how come spread pricing can exist. Because spread pricing is when the PBM charges the plan sponsor more than they are paying the pharmacy, pocketing the difference, and then calling what they pocket a trade secret—even if it’s the plan sponsor whose butt is on the line to make sure that what the PBM is pocketing is fair and reasonable compensation. I mean, if only J&J had listened to this show (EP428). Here’s a link to the lawsuit, which is about J&J paying ridiculous amounts in spread pricing.

If what I just said is really confusing, I’m gonna validate that and say, “Yeah, it is really confusing.” And to a certain extent, that might be the main point. Where there’s mystery, there’s margin and all of that.

Here’s what Dawn Cornelis said on LinkedIn in response to an article about the lawsuit: “Data accessibility lies at the heart of mitigating a fiduciary lawsuit. It all begins with gaining access to your data. But let’s be clear—it’s not an easy feat. The major hurdle? Procuring accurate data from your TPA [third-party administrator]. And that’s just the first step. The subsequent challenge involves analyzing this data, a task best handled by a skilled healthcare data analyst—yet another formidable undertaking.”

The one acronym in this whole stew that is not questionable at all is the NADAC. So, let’s talk about the NADAC for a moment, the National Average Drug Acquisition Cost Price Benchmark. I was really thrilled to get Luke Slindee to be my guest today—or one reason I was so thrilled—is because Luke works for the accounting firm who, on behalf of CMS (Centers for Medicare & Medicaid Services) and the federal government, administers this NADAC, the National Average Drug Acquisition Cost. (Here’s a good NADAC explainer if you’re interested.)

In brief, NADAC was jointly developed by the Centers for Medicare & Medicaid Services, and it calculates the average price that pharmacies pay for prescription drugs. NADAC is based on a retail price survey.

My guest today, as aforementioned, is Luke Slindee. He is a second-generation pharmacist. His family owned a pharmacy in Minnesota when he was growing up. Now he is a senior pharmacy consultant for Myers and Stauffer, which is the accounting firm that calculates the NADAC Price Benchmark on behalf of CMS and the federal government.

Also mentioned in this episode are Mark Cuban; Ferrin Williams, PharmD, MBA; Blueberry Pharmacy; Vinay Patel; Benjamin Jolley, PharmD; Scott Haas; Paul Holmes; Dawn Cornelis; Capital Rx; Myers and Stauffer LC; Adam Fein; Joey Dizenhouse; Steven Quimby, MD; and Antonio Ciaccia.

For additional information, go to data.medicaid.gov. You can also follow Luke on LinkedIn.

Luke Slindee, PharmD, is a second-generation pharmacist with a background in independent pharmacy, chain pharmacy, data analytics, and prescription drug pricing. He currently supports public drug pricing transparency benchmarks and is an advocate for pharmacy reimbursement reform and antitrust enforcement in healthcare.

 09:52 Why is it important for plan sponsors to understand the going rate for every point in the supply chain?

10:21 How do manufacturers come up with a list price?

10:40 What does AWP stand for?

10:59 What does WAC stand for?

11:06 How are AWP and WAC numbers chosen by the manufacturer?

13:22 What is the difference between AWP and WAC?

14:54 How much are wholesalers paying to manufacturers?

16:43 How much is the pharmacy paying for branded drugs from a wholesaler?

17:34 Why might pharmacies be buying drugs for less than what wholesalers are paying?

18:17 Substack article by Benjamin Jolley, PharmD, on this topic.

19:22 EP423 with Joey Dizenhouse.

20:33 Why do things get weird when a PBM gets involved?

21:58 How does all of this work for generic manufacturers?

25:20 EP344 with Steven Quimby, MD.

26:15 How did Civica Rx come about?

32:21 What’s the difference between the NADAC and the AWP value?

36:04 Luke discusses the downstream effects to pharmacies. 

Recent past interviews:

Click a guest’s name for their latest RHV episode!

Julie Selesnick, Rik Renard, AJ Loiacono (Encore! EP379), Nina Lathia, Marshall Allen, Stacey Richter (INBW39), Peter Hayes, Joey Dizenhouse, Benjamin Jolley, Emily Kagan Trenchard (Encore! EP392)

[00:00:00] Episode 429. Following the dollar through pharmacy acronyms like WAC, AWP, and NAIDAC.

[00:00:10] Today I speak with Luke Slindy.

[00:00:21] American healthcare entrepreneurs and executives you want to know, talking.

[00:00:25] We're relentlessly seeking value.

[00:00:29] Today we're talking about pharmacy acronyms or terms like AWP and WAC and not really an

[00:00:37] acronym, but we'll also talk pharmacy list prices, rebates, discounts.

[00:00:41] We also have NAIDAC, but that's slightly off to the side

[00:00:45] for reasons we'll get to in a sec.

[00:00:47] Most of these acronyms refer to a number

[00:00:49] with a dollar sign in front of it,

[00:00:51] and it's hell on wheels to figure out if and or,

[00:00:54] to what extent that number reflects what is going on

[00:00:58] in the real world, especially if you are a patient

[00:01:01] or a plan sponsor, and all you see is the list price

[00:01:04] that pharma

[00:01:05] puts out on one side of the storyboard, and then what the patient pays or if you're lucky,

[00:01:10] what the plan pays for the drug on the way other side of the whole chain of events.

[00:01:15] What's a black box a lot of times for patients and plant sponsors is what goes on in the

[00:01:21] middle wherein many middle people get their mitts in the middle. Wherein, many middle people get their midst

[00:01:25] on the transaction.

[00:01:26] Real quick here, let's run through

[00:01:28] the Mr. Rogers neighborhood of all of these middle people

[00:01:31] right now and we're gonna do this really briefly.

[00:01:34] Most of you are already going to know most of this

[00:01:37] but I just wanna remind you so that when my guest today,

[00:01:40] Luke Slindy and I kick into the conversation

[00:01:43] about the acronyms and the terms and we try

[00:01:45] to follow the dollar. Yeah, you can put a name to a face. All right. So first, we have pharma

[00:01:51] manufacturers, the form of manufacturer. And this is largely going to be true, whether it's a branded

[00:01:56] drug or a generic pharma manufacturer. But the manufacturer sets a list price. This list price

[00:02:02] is going to be called an AWP or a WAC price.

[00:02:05] And we're going to get into the differences

[00:02:07] in what those terms actually mean in the show that follows.

[00:02:10] But pharma decides their price point.

[00:02:13] They go to wholesalers with that price.

[00:02:16] Wholesalers say they want a discount to purchase the product.

[00:02:20] Some kind of rebate or discount is negotiated.

[00:02:23] Now the wholesalers have the drug and they get calls from pharmacies.

[00:02:27] Pharmacies have patients who have scripts for that drug, so the pharmacies need to buy the drug.

[00:02:32] What price does the pharmacy now pay the wholesaler for the drug?

[00:02:36] Short answer, it's nuts.

[00:02:38] It's nuts how the wholesalers decide what to charge the pharmacies for the drug.

[00:02:44] We talk about that in the interview that follows, but suffice to say that now we have

[00:02:49] the list price turning into whatever price the pharmacies wound up paying to get the

[00:02:53] drug from the wholesalers for.

[00:02:55] And anyway, you cut it, the wholesalers are making some money.

[00:02:59] Okay, now we get to the part where we're figuring out how much the patient or the plan sponsor

[00:03:06] will pay to pick up that drug that started at the pharma manufacturers and went to the

[00:03:10] wholesalers and now is at the pharmacy.

[00:03:13] How much are the patients going to pay?

[00:03:14] How much are the plan sponsor is going to pay?

[00:03:16] Have you spent any time in the real world, not the drug supply chain world?

[00:03:21] What you'd expect to happen next is that the patient would go into the

[00:03:26] pharmacy and the pharmacist would charge a markup and or a dispensing fee on the price

[00:03:32] that they bought the drug from the wholesaler for like that be normal.

[00:03:36] And this can be the case when patients pay cash, listen to the show with Mark Cuban,

[00:03:42] who started a pharmacy called cost plus drugs.

[00:03:45] Get it?

[00:03:46] Their prices are cost plus.

[00:03:48] You have had other pharmacies for years doing similar things like Blueberry and Pittsburgh.

[00:03:54] They get the drug, they buy it from a wholesaler or etc.

[00:03:58] But they'd buy the drug for some price and then they sell it to their customers, i.e.

[00:04:03] patients at their cost plus.

[00:04:05] But most of the time in pharmacy supply chain world, things don't work that way because

[00:04:11] many patients have insurance.

[00:04:13] When a patient walks into the pharmacy, someone has to figure out how much the patient owes

[00:04:18] and how much their insurance will cover, right?

[00:04:22] So enter PBMs.

[00:04:23] They originally started out doing this math,

[00:04:26] i.e. adjudicating claims,

[00:04:28] figuring out what the out-of-pocket will be for the patient

[00:04:31] and then what the insurance will cover.

[00:04:34] Then, drugs started to get really expensive

[00:04:36] and a few other developments.

[00:04:37] And then all of a sudden, we have PBMs negotiating with pharma

[00:04:41] for how much of a rebate the PBM is going to demand

[00:04:44] for the PBBM to put the

[00:04:46] manufacturer drug on

[00:04:47] Formulary the PBM also is determining how much they will pay the pharmacy for said drug on behalf of planned sponsors in

[00:04:54] In addition to doing the math for how much the patient will pay

[00:04:57] So let me say that again because it kind of begs at what now with eyebrows sky high as the appropriate

[00:05:04] Response to what I just said.

[00:05:06] Especially if you think through the ramifications here,

[00:05:09] ramifications which I discuss at length

[00:05:11] with a Vinay Petzel, Benjamin, Jolly, Scott Haas,

[00:05:13] Paul Holmes and others.

[00:05:15] So again, the PBM is not just adjudicating claims,

[00:05:18] they are also negotiating rebates from pharma.

[00:05:22] So plan sponsors do not have to pay the full amount that the wholesalers

[00:05:25] paid pharma and that the pharmacies paid the wholesalers, which maybe is a lot of money.

[00:05:30] The PBM's are like, hey, pharma, you need to give me a piece of your action because we,

[00:05:35] the PBM, have big market power. I serve 100 million patients or something. So, if you want

[00:05:40] access to my 100 million lives, you got to shell it out. You got to shell me out some rebates.

[00:05:46] So, fine.

[00:05:47] Pharma gives the PBM some amount of money in the form of a rebate.

[00:05:51] And it has to work that way if you think about it because the drug was originally sold to

[00:05:54] the wholesalers.

[00:05:55] You see what I'm saying?

[00:05:56] So, the pharma company has to give the PBM a separate rebate amount.

[00:06:01] This is in addition to how much the PBM told the plans sponsor, the plans sponsor owes

[00:06:06] for the drug, which is also paid to the PBM.

[00:06:10] But now PBM is also still in charge of adjudicating the claim, so they're telling the pharmacy

[00:06:15] how much to charge the patient.

[00:06:17] Somehow or another, also the PBM also got itself in charge of deciding how much money

[00:06:21] the pharmacy itself would be reimbursed by that PBM. In the rest of the world, the pharmacy might tell the PBM like,

[00:06:27] hey, this is the price, but not in pharmacy supply chain world. In pharmacy supply chain

[00:06:31] world, the PBM tells the pharmacy how much it's going to pay the end. And this, my friend, is how

[00:06:37] so often pharmacies get themselves in the pickle of having to pay the wholesaler one price to get

[00:06:43] the drug while they get reimbursed a totally different price to dispense the drug.

[00:06:48] And because independence have very little negotiating leverage on actually either side of that equation,

[00:06:54] they so very often buy high and sell low. Please listen to the shows with Benjamin,

[00:07:00] Jali and Vinay, Pateau, where we get into this in a lot of detail. But I just want to emphasize this point.

[00:07:07] All of that whole drug supply chain I just went through were the manufacturer sells to

[00:07:12] the wholesaler who sells to the pharmacy and the PBM pays the pharmacy and the patient

[00:07:16] is paying something and the plan sponsor is paying something.

[00:07:20] Many of the middleman transactions in there happen under the cover of darkness a lot of times.

[00:07:25] If I'm a plan sponsor, do I have any idea how much the PBM paid the pharmacy for any particular

[00:07:32] drug? Unless you're good at looking at the NAIDAC numbers more on this coming up? No.

[00:07:39] I do not have any idea what a fair price for that drug actually is and how much people are making

[00:07:46] on the back of that drug as it goes through the supply chain.

[00:07:50] And this, my friends, is how come spread pricing can exist?

[00:07:54] Because spread pricing is when the PBM charges the plan sponsor more than they are paying

[00:07:59] the pharmacy, pocketing the difference, and then calling what they pocket a trade secret.

[00:08:05] Even if it's the plan sponsor whose butt is on the line to make sure that what the PBM

[00:08:10] is pocketing is fair and reasonable compensation.

[00:08:12] I mean, if only J&J had listened to the show, link in the show notes to the lawsuit, which

[00:08:18] is about J&J paying ridiculous amounts and spread pricing.

[00:08:22] If what I just said is really confusing, I'm gonna validate that and

[00:08:26] say, yeah, it is really confusing. And to a certain extent, that might be the main point where there's

[00:08:31] mystery, there's margin and all of that. The one acronym in this whole stew that is not questionable

[00:08:39] at all is the NAIDAC. So let's talk about the NAIDAC for a moment, the national average drug

[00:08:44] acquisition cost Price benchmark.

[00:08:46] I was really thrilled to get Luke Slindy

[00:08:48] to be my guest today, or one reason I was so thrilled,

[00:08:51] is because Luke works for the accounting firm,

[00:08:54] who on behalf of CMS and the federal government

[00:08:56] administers this NAIDAC,

[00:08:59] the National Average Drug Acquisition Cost.

[00:09:02] I'll put a good NAIDAC explainer in the show notes if you're interested, but in brief,

[00:09:08] NAIDAC was jointly developed by the Centers for Medicare and Medicaid Services and it

[00:09:13] calculates the average price that pharmacies pay for prescription drugs.

[00:09:19] NAIDAC is based on a retail price survey.

[00:09:22] My guest today, as a fore mentioned, is Luke Slindy. He is

[00:09:25] a second generation pharmacist, his family owned a pharmacy in Minnesota when he was

[00:09:30] growing up. Now he is a senior pharmacy consultant for Myers and Stauffer, which is the accounting

[00:09:36] firm that calculates the NAIDAC price benchmark on behalf of CMS and the federal government.

[00:09:42] My name is Stacey Richter. This podcast is sponsored by a Ventria Health Group.

[00:09:47] Luke Slindy, welcome to Relentless Health Value.

[00:09:49] Thanks. Happy to be here.

[00:09:51] I'm a big fan of the podcast.

[00:09:52] If I'm a plan sponsor, you'd think in an ideal world,

[00:09:55] the plan sponsor would understand

[00:09:57] how much they're paying for the product

[00:10:00] and how much they're paying to the vendor

[00:10:02] that the vendor's putting in their pocket.

[00:10:04] That would seem normal.

[00:10:05] Yeah, I mean, everyone involved in the process

[00:10:08] is necessary and is providing a valuable service.

[00:10:11] It's just that it's important to understand exactly

[00:10:15] what the going rate for providing that service

[00:10:18] is across each of the steps in the supply chain.

[00:10:21] If we started at the very beginning,

[00:10:22] and let's talk about a branded drug right now,

[00:10:25] so we have a pharma manufacturer,

[00:10:28] and those pharma manufacturers are setting a price.

[00:10:33] How is it calculated?

[00:10:35] First of all, it's not calculated.

[00:10:37] We refer to that as a list price.

[00:10:40] So in general, there's two major industry versions

[00:10:44] of list prices,

[00:10:45] AWP, which stands for average wholesale price,

[00:10:49] although those three words are kind of a misnomer at this point.

[00:10:52] Yeah, I've also heard it stands for eight what's paid.

[00:10:55] Yes, that's one of the common comments.

[00:10:57] So that AWP is one, and then the other one is wholesale acquisition cost or WAC.

[00:11:03] And again, it's not calculated.

[00:11:06] Both the AWP and the WAC are numbers

[00:11:10] that are at the sole discretion

[00:11:12] of the manufacturer of the product.

[00:11:15] And they can just pick any number they want.

[00:11:19] And they transmit that information out to the public

[00:11:22] mostly by providing the information

[00:11:24] to the major pricing databases,

[00:11:27] Compendia that exist in our industry.

[00:11:29] So specifically, first data bank,

[00:11:32] Metaspan, there are a couple others,

[00:11:34] but for AWP and WAC, those are the list prices.

[00:11:37] The manufacturer, they just pick a number that they want,

[00:11:41] and then that gets transmitted to the Compendia, and then the entire industry

[00:11:46] basically gets the information from the Compendia.

[00:11:48] There was a bunch of public information relative to how does pharma pick those list prices.

[00:11:54] It was very much, how much do we think people will pay?

[00:11:58] And that's normal in the world.

[00:11:59] Like if you're manufacturing pretty much anything, you're going to figure out what your costs

[00:12:04] are, and then you figure out what your market will bear.

[00:12:06] That is certainly true,

[00:12:07] although I would just add, in addition to that,

[00:12:11] now with the rise of PBMs

[00:12:13] and what's been called the gross to net bubble,

[00:12:16] shout out to Adam Fine.

[00:12:18] So yes, when they're setting the list price,

[00:12:20] the manufacturers are choosing what will the market bear,

[00:12:23] but then they also have to take

[00:12:25] into consideration what rebate am I going to have to pay in order to get this drug onto the

[00:12:31] formulary. So for example, if you know that you're going to have to pay a certain percentage or a

[00:12:36] certain dollar amount of a rebate in order to gain market access, then that would also get

[00:12:40] factored into the list price that they set. Because if you know ahead of time that you have to pay a rebate,

[00:12:46] you're going to set the list price higher than you would above and beyond

[00:12:50] whatever your net money that you're actually going to make would be.

[00:12:54] I think the point that you're making is that in this supply chain,

[00:12:57] we've got PBM's who are trying to maximize their rebates.

[00:13:01] You want to make sure your customer is happy.

[00:13:03] And if you know your customer wants to maximize those rebates, you want to make sure your customer's happy. And if you know your customer wants to maximize those rebates, then the higher your list price,

[00:13:09] the bigger the rebate that you can subsequently offer.

[00:13:13] So there's reasons why those AWPs or WACs, whatever you want to call that list price,

[00:13:19] is as high as it is.

[00:13:22] Correct.

[00:13:23] What's the difference between AWP and WAC?

[00:13:25] Are they synonyms?

[00:13:26] For branded drugs that do not have generic competition,

[00:13:30] the relationship between the WAC and the AWP is fixed.

[00:13:35] So usually the AWP is the WAC times 1.2.

[00:13:40] There's some historical basis for all of that.

[00:13:43] Most of it has to do with people determining that

[00:13:46] the AWP-based system was problematic and trying to come up with an alternative. Unfortunately,

[00:13:53] the alternative that they came up with, which is WAC, basically, they didn't change any of the

[00:13:58] underlying concepts. And so the same problematic things that happened with AWP also happened to WAC.

[00:14:05] And so now basically we just have two different versions of list prices that aren't particularly

[00:14:10] helpful. Okay, the pharma company, they set their list price and to the points that you made,

[00:14:17] if we're talking about WAC and just to clarify, the WAC price is 20% less than AWP.

[00:14:23] Is that a rule? It's a fixed ratio. Yeah. Okay, so whatever the AWP is, the WAC price is 20% less than AWP. Is that a rule? It's a fixed ratio. Yeah.

[00:14:25] Okay. So whatever the AWP is, the whack price is going to be 20% less than that the end.

[00:14:30] For branded drugs.

[00:14:32] For branded drugs. But if I'm a pharma manufacturer, I've set my price, I tell the market, this

[00:14:37] is my price. So keeping in mind that who's going to buy the drug from the pharma company

[00:14:43] is a wholesaler who's going to drive

[00:14:45] a truck over and pick the drug up. They've got refrigerators and they've got their storing it

[00:14:49] and making sure that their safety in the supply chain, etc. So how much does the pharma company

[00:14:57] sell the drug to the wholesaler for? I don't have any insider information exactly to the prices that wholesalers purchase from

[00:15:07] manufacturers, but I do have access to the information, one link down the supply chain

[00:15:12] of where pharmacies are buying from wholesalers.

[00:15:15] And so you can kind of impute and guesstimate what wholesalers are paying to the manufacturers

[00:15:22] and so forth again for a branded drug where there's

[00:15:25] no generic competition, the wholesalers are typically purchasing below the list prices.

[00:15:33] So that's not particularly shocking. Usually if I were to put a very gas number on it,

[00:15:40] for most branded drugs, wholesalers are typically purchasing drugs around a 2 to 2.5% discount from the WAC,

[00:15:50] which then would translate to a 20-ish discount from the AWP.

[00:15:57] On the buy side, pharmacies and wholesalers and manufacturers tend to use WAC more than

[00:16:03] they do AWP.

[00:16:04] On the sell side, it might be different, but yes.

[00:16:06] So to answer your question in a nutshell,

[00:16:09] there is a relationship to what wholesalers are paying

[00:16:12] for branded drugs to the manufacturers,

[00:16:15] to the list prices.

[00:16:17] It's usually about a two to two and a half percent

[00:16:20] discount from the WAC value.

[00:16:22] You know, I guess when we talk about rebates and discounts,

[00:16:24] a lot of times in the pharma supply chain,

[00:16:27] we talk about them in the context of PBMs,

[00:16:30] but there's a whole other discount rebate thing going on

[00:16:33] with the wholesalers.

[00:16:35] It sounds like off of the WAC price,

[00:16:38] there's a 2 to 2.5% discount,

[00:16:41] and you have managed to figure that out.

[00:16:43] So then the wholesaler is selling it to the pharmacy.

[00:16:46] How much is the pharmacy buying it for from the wholesaler?

[00:16:50] This is where we get into the information

[00:16:53] that is provided to us from the pharmacies

[00:16:56] that voluntarily provide this information.

[00:16:58] And this is where your NAIDAC information comes into play.

[00:17:02] The ingredient cost is available via the public

[00:17:05] NAIDAC data benchmark.

[00:17:07] For a branded drug, you will see a range when you calculate

[00:17:13] the average, which we do for the NAIDAC process.

[00:17:16] It usually comes out to around a 4% discount from WAC.

[00:17:21] So as a general rule on branded drugs, you can assume that pharmacies

[00:17:27] are paying about a 4% discount from WAC to acquire from the wholesaler.

[00:17:31] So the wholesaler, okay, I'm confused because it sounds like the wholesalers are buying

[00:17:37] for 2.5% under WAC and selling for 4% under WAC, which is less than they are buying the drugs for.

[00:17:47] There's another factor that comes into play, which would probably have to be a different podcast,

[00:17:52] but when pharmacies are purchasing drugs from a wholesaler, there is an explicit relationship

[00:18:00] tied between the purchase price of the brand drugs that pharmacy purchases

[00:18:06] to the volume of generic drugs that a pharmacy purchases from the same wholesaler.

[00:18:11] Okay.

[00:18:12] So this is what we had discussed in an earlier conversation.

[00:18:18] And I'm remembering that you told me that Benjamin Jolly also wrote an amazing sub stack

[00:18:22] on this exact topic, which I will link to

[00:18:25] in the show notes.

[00:18:26] So wholesalers make the purchase price of brands dependent upon the volume of generics

[00:18:32] that they have purchased.

[00:18:34] And so you have a situation where the purchase price of the brands actually become dependent

[00:18:38] upon the quantity or the volume of generic drugs you buy from the same wholesaler.

[00:18:43] If we're thinking about this from a pharmacy standpoint, if I'm an indie, if I'm a little

[00:18:47] indie pharmacy, then my drugs are more expensive.

[00:18:51] The branded drugs that I'm buying and probably the generics as well is my takeaway from everything

[00:18:56] that you said, that there's volume discounts here for what the acquisition costs of the

[00:19:00] drugs are going to be.

[00:19:02] Yeah, I would say that on branded drugs, the differential between the size of the pharmacy

[00:19:09] chain organization versus a little pharmacy is probably a lot smaller than most people

[00:19:14] think on branded drugs. The Delta is really on the generic side.

[00:19:18] The other interesting takeaway that I have from what you just said and Joey Deason House

[00:19:23] made this really clear in a recent episode

[00:19:26] where he said, pay attention to who benefits when the prices are higher. And so when you were

[00:19:34] talking, I was immediately thinking about how in a normal circumstance, the customer who's buying

[00:19:41] something is the one that kind of holds like supply and demand, right? Like you're holding the customer's job in a way

[00:19:47] for a functioning free market is to hold the price down.

[00:19:51] But when we have a case where the one buying it

[00:19:53] also has a benefit to see the price be higher.

[00:19:56] Unfortunately, we've built a system

[00:19:58] where every single player in the system

[00:20:01] is benefiting from higher drug prices.

[00:20:03] So it shouldn't be a mystery that the system

[00:20:05] produces high drug prices.

[00:20:07] Yeah, free markets are amazing,

[00:20:09] but we have a situation here where at a basic,

[00:20:11] even just microeconomics apply in demand standpoint.

[00:20:14] Houston, we have a problem.

[00:20:16] So, okay, then we have the situation

[00:20:20] where the pharmacy sells the drug to a patient.

[00:20:25] If I'm a pharmacy, can I sell the drug?

[00:20:27] I mean, it's my store.

[00:20:29] Can I sell the drug for whatever price I want to a patient?

[00:20:32] Absolutely.

[00:20:33] If a PBM is not involved,

[00:20:35] you can set any price you want

[00:20:37] and sell it to the patient

[00:20:39] for any price that they're willing to accept.

[00:20:41] Well, that is a pretty big caveat.

[00:20:43] It is.

[00:20:44] If a PBM is not involved, because a lot of patients will go into the pharmacy with an

[00:20:50] insurance card.

[00:20:51] So most pharmacies will have a contract with a pharmacy benefit manager.

[00:20:56] And this is where things get weird because you've got a pharmacy who just bought the

[00:21:00] drug using that whole supply chain that we just talked about.

[00:21:04] But if that patient has insurance,

[00:21:05] then there's this whole other operation that goes on.

[00:21:08] Wherein' a pharmacy benefit manager

[00:21:12] is getting paid by a plan sponsor to reimburse the pharmacy

[00:21:15] and the PBM will reimburse the pharmacy

[00:21:17] based on a different set of math.

[00:21:19] It doesn't have anything to do

[00:21:21] with how much the pharmacy bought the drug for,

[00:21:24] which is why you winds up with these weird situations where these pharmacies are underwater, where

[00:21:28] their acquisition costs are actually higher, then what they're getting reimbursed from

[00:21:31] the PBM.

[00:21:32] Correct.

[00:21:33] All right, so we started out when we were defining AWP and Wack, and I said very specifically,

[00:21:39] hey, let's talk about this if it's a branded drug with no generic competition.

[00:21:44] But if we go way back up to the top now, and we're talking about this if it's a branded drug with no generic competition. But if we go way back up to the top now and we're talking about this supply chain from

[00:21:48] a generic standpoint, we started talking about AWPs and WAC prices.

[00:21:54] So pharma manufacturer, let's just say it's generic manufacturer now.

[00:21:58] If I'm a generic manufacturer, do I also set an AWP and a WAC price?

[00:22:05] How does it work at the very beginning

[00:22:06] if I'm a generic manufacturer selling to a wholesaler?

[00:22:09] So everything in general is the same,

[00:22:12] except for the relationship between the list prices

[00:22:18] that are set by the manufacturer

[00:22:20] and the actual sales prices as the drug flows

[00:22:23] from manufacturer to wholesaler to pharmacy to PPM.

[00:22:27] As I said previously, the relationship between what happens on a branded drug as it moves through the supply chain is not particularly unknown.

[00:22:39] Once you kind of have an understanding of the percentage relationships between the different things, if you know one number, you can kind of impute the rest. None of that is true on

[00:22:48] the generic side. And so for generic drugs, again, the manufacturer is responsible for

[00:22:54] setting an AWP and a WAC. Those numbers can be literally anything.

[00:23:00] So in other words, the WAC price isn't always 20% less than AWP.

[00:23:04] Correct. Eventually, we can get into an example here that provides some of the just help literally anything. So in other words, the whack price isn't always 20% less than AWP.

[00:23:05] Correct.

[00:23:05] Eventually we can get into an example here that provides some of the just how absurd this

[00:23:09] gets.

[00:23:10] Like the word I usually use for AWP and whack values for generic drugs is gibberish.

[00:23:17] It's not an exaggeration.

[00:23:18] It's just a number that gets made up.

[00:23:20] It does not have any relationship whatsoever to what is actually being sold into the wholesalers

[00:23:27] and then the wholesaler selling to pharmacies. And so that predictable relationship for generic

[00:23:33] drugs just goes out the window. So if I'm a pharma manufacturer on the branded side,

[00:23:38] there's actually some math that goes on on the pharma side to try to figure out how high they need to make

[00:23:45] it be so that they can make sure that they're attractive to PBMs and get on formularies.

[00:23:51] And there's this whole thing called a rebate cliff, right?

[00:23:54] So if there's another brand on formularie and that PBM is making Buku dollars on that

[00:24:00] other brand, like they're not going to put a new brand on formularie and then jeopardize the money that they're getting off of that other brand, like they're not going to put a new brand on Formula E and then jeopardize

[00:24:05] the money that they're getting off of that other brand. So there's considerations that

[00:24:09] are happening on the pharma side as they contemplate what they want their list prices to be.

[00:24:15] Is there any similarity going on on the generic side?

[00:24:18] There are incentives and there are considerations. They're probably just different incentives and considerations.

[00:24:25] I would summarize it as there are perverse incentives because basically the profit

[00:24:31] margins to everyone, wholesalers, pharmacies, PBMs, the profit margins on

[00:24:38] generic drugs are sky high, expressed as a percentage.

[00:24:43] It's not that the dollar amounts are particularly high, expressed as a percentage. It's not that the dollar amounts are particularly high,

[00:24:47] but as a percentage profitability,

[00:24:50] that is where all of the profits come from

[00:24:53] in the supply chain basically, is on the generic side.

[00:24:56] And this is actually fundamentally different

[00:24:58] from the branded side because on the branded side,

[00:25:00] the percentages are pretty low,

[00:25:01] but because the drugs are really expensive,

[00:25:03] you know, if it's a $100,000 drug or something,

[00:25:06] 2% is not jump change.

[00:25:08] But if we're talking about a generic,

[00:25:10] where it's 47 cents,

[00:25:12] then somebody might be making a 100% profit margin,

[00:25:16] but because the vast majority of drugs

[00:25:18] prescribed in this country,

[00:25:20] I think I interviewed Dr. Steve Quimby about this,

[00:25:23] and it was like billions of generic drug prescriptions

[00:25:27] that happen in this country every year. So 50 cents times billions is, yeah, it's a volume game

[00:25:33] there. If you look at these large companies like the Big Free wholesalers or the big

[00:25:37] pharmacy chains or to a certain extent, the PBMs, the vast majority of the profits come from the generic side. And the profitability is downstream of the fact that no one knows what a reasonable price for

[00:25:51] a generic drug is. Antonio Chacha says where there's mystery, there's margin, and I mean,

[00:25:56] that's kind of it in a nutshell. The profitability that comes on the generic side is available because

[00:26:04] no one really knows what a reasonable

[00:26:06] market price for a generic drug is. And so that just introduces a lot of opportunities for

[00:26:11] high-profit sand or price gouging, depending upon your perspective.

[00:26:15] Which is why, you know, like we have CivicRx right now. It's a joint venture with a bunch of

[00:26:20] hospitals who got together, who started manufacturing their own generic drugs. Partly it was because of drug shortages,

[00:26:27] but also it was because there's a bunch of people

[00:26:29] who are like, maybe I should just,

[00:26:31] why don't I just manufacture my own drugs?

[00:26:32] This is nuts.

[00:26:34] When people look at market dysfunction,

[00:26:36] and now that this has gotten to the point

[00:26:38] where it's even been included in like congressional hearings

[00:26:41] and things like that, the area where things get to be the most absurd

[00:26:46] is this kind of oxymoronic space called generic specialty.

[00:26:51] And there are particular drugs that have really been focused

[00:26:53] on quite a bit in the public.

[00:26:55] You know, Gleevec or Imatinib is certainly one,

[00:26:59] Truvada and the generic equivalent of that,

[00:27:02] tech-federa dimethylcumarate.

[00:27:04] So there are some quintessential examples

[00:27:07] that I think have made it out there

[00:27:10] into the drug-cricing nerd ether, if you will.

[00:27:14] Maybe we should just run through a quick example

[00:27:18] so that it becomes clear the magnitude

[00:27:21] of what we're talking about.

[00:27:22] Could you just give an example of maybe one drug?

[00:27:24] Definitely. Another example of maybe one drug? Definitely.

[00:27:25] Another example of a drug that is also kind of

[00:27:28] in that generic specialty space.

[00:27:30] The drug, I'm question, the original brand version

[00:27:33] of the drug is called Abagio.

[00:27:35] It's a drug used to treat multiple sclerosis.

[00:27:38] And prior to March of 2023,

[00:27:42] so a little, a little under a year ago,

[00:27:44] it was brand only. There was no

[00:27:46] generic competition. So, Abajio, the brand version was the only one that was available.

[00:27:52] And currently, the WAC value of that drug is about $311 per tablet. And then because of

[00:28:00] that fixed ratio between WAC and AWP on branded NDCs, then the AWP value

[00:28:07] is the WAC times 1.2, which is about $374-ish dollars per tablet. So again, 311, 374, those

[00:28:18] are the various list prices. Per tablet, what we're talking about here? So if somebody's taking

[00:28:23] it once a day. Yep, every day. Okay. So basically, if we're looking at a. So if somebody's taking it once a day, every day.

[00:28:26] So basically if we're looking at a 30-day supply, it's 311 or 374. If we're talking about

[00:28:31] AWP times 30. When the generic competition entered in very quickly, the true market prices that are

[00:28:40] reflected in terms of what wholesalers were selling the drugs to pharmacies, plummeted.

[00:28:46] And I mean, way, way, way down,

[00:28:49] almost to a comic extent.

[00:28:51] And so at the current moment,

[00:28:52] the NAIDAC for the generic equivalents of this drug

[00:28:56] sit at 69 cents per tablet.

[00:28:59] So we went from the list price previously was,

[00:29:03] the WAC was 311, the AWS was around $374 per tablet. So we went from the list price previously was the WAC was 311, the AWS was

[00:29:06] around $374 per tablet. Now it is 69 cents. That's what the pharmacies are actually paying

[00:29:14] the wholesalers approximately to put that drug on the shelves. But this is the point I'm

[00:29:18] trying to make. If you look at the WAC and the AWP values for those generic NDCs, which

[00:29:27] the competitively can be sourced around 69 cents a tablet, there's a range.

[00:29:32] So the WAC value, and this is where I talk about it being gibberish.

[00:29:36] And by the way, there are now 11 generic manufacturers that are all competing in this space.

[00:29:42] So we went from having one, right?

[00:29:44] It was just Synophie. And now there are 11 generic manufacturers that in this space. So we went from having one, right? It was just Synophie,

[00:29:45] and now there are 11 generic manufacturers

[00:29:48] that produce this drug.

[00:29:49] The lowest WAC is about a dollar,

[00:29:53] and the highest WAC is $68 per tablet.

[00:29:56] So that just shows you the range

[00:29:59] on that particular drug in terms of the WAC.

[00:30:02] And then on the AWP side,

[00:30:04] the lowest AWP is $10

[00:30:07] and the highest AWP is $343.

[00:30:11] So to take that example of the AWP value on this drug,

[00:30:15] which is, it's the same NDC.

[00:30:17] So the pharmacies are purchasing this drug for,

[00:30:21] and I know you're using pharmacy talk,

[00:30:22] which is per tablet, I'm using patient talk,

[00:30:24] which is how much did the prescription cost? Basically, a pharmacy is buying a 30-day

[00:30:27] supply for $20, but at the beginning of the food chain, it could be $1 to $68 or $10 to

[00:30:35] $343, right? So like, actually, there's discounts that are happening along the way, somehow or

[00:30:41] another off of the original price. This is where the word gibberish comes into play.

[00:30:46] So on generic drugs and in particular on generic specialty drugs, the AWP and the WAC

[00:30:54] values literally don't mean anything.

[00:30:57] But what's scary is that on the pay side, which can affect patient out of pocket, of course, and certainly affect

[00:31:05] the plant sponsors. There is this incredible delta between what the pharmacies are actually

[00:31:12] sourcing the drug for and what the manufacturer set list of braces are. And then if AWS is

[00:31:18] the basis of your contract, and that's what you're paying off of.

[00:31:21] And so when you say the basis of your contract, whose contract the pharmacy or the plan sponsor?

[00:31:27] Well, either, but probably the more concerning one

[00:31:31] to your audience would be the contract

[00:31:33] between the PBM and the plan sponsor.

[00:31:35] So you could literally be looking at a situation

[00:31:37] where the pharmacy is buying the drug for 69 cents a tablet.

[00:31:42] They're getting paid probably a little bit over that, you know,

[00:31:46] from the PBM. So let's say 75 cents a tablet or who knows. And then the PBM is turning around

[00:31:53] and charging the health plan sponsor a number based upon the AWP value, which is $343.

[00:32:00] A tablet, which could be a tablet. Yes. It's less.

[00:32:05] The brand it is 370 Marie, the highest generic AWS 343.

[00:32:08] So it's less than the brand, but not by much.

[00:32:11] But yeah, basically it creates these truly absurd situations.

[00:32:16] Again, these have been put on charts and congressional hearings and stuff like that.

[00:32:20] And so in general on the generic side, and especially on the generic specialty side,

[00:32:26] the framing of this that I use is the differential between the NAIDAC, which is that representation

[00:32:33] of what pharmacies are actually paying the wholesalers to source something, and the AWP value.

[00:32:38] The difference between the NAIDAC and the AWP value is the bigger the difference is there,

[00:32:44] the more rope that various intermediaries are given

[00:32:48] to hang people with.

[00:32:49] In other words, the more money the middlemen are taking.

[00:32:51] Yeah, it just creates these really absurd situations

[00:32:54] and there's been a lot of criticisms about the PBMs

[00:32:57] because on a drug like this,

[00:33:00] you're not likely to get it at a Walgreens.

[00:33:02] You're not likely to get it at a mom and pop pharmacy.

[00:33:05] The dispensing of these drugs is usually strongly controlled

[00:33:09] so that the PBM will force you to get it

[00:33:12] from their pharmacy that they call.

[00:33:14] Well, of course they would because they're making

[00:33:16] that much money.

[00:33:17] Correct.

[00:33:17] And so this is an area that many people besides me

[00:33:22] have put a lot, tried to shine a light on.

[00:33:25] As the criticisms around PBMs with respect

[00:33:29] to what they do with a manufacturer rebates

[00:33:32] on branded drugs kind of amped up,

[00:33:33] then the PBMs basically, they're kind of like a ball of mercury

[00:33:37] if you hit it with a hammer, right?

[00:33:38] They're just gonna go do something else

[00:33:40] and figure out other ways to make money.

[00:33:42] And this is one of the spaces that they moved in

[00:33:44] is this generic specialty space where they pay themselves

[00:33:49] because they own the pharmacy and they do that

[00:33:51] based upon the AWP value and then turn around

[00:33:54] and charge that to the planned sponsor

[00:33:56] and then the delta between the 69 cents

[00:33:59] they're buying it for and the 343 AWP value

[00:34:02] is kept.

[00:34:03] Well, that is a great example of just how much slash

[00:34:07] there is in the middle.

[00:34:09] In other words, for slashes waste

[00:34:10] and let's not forget that someone's waste

[00:34:12] is someone else's profit.

[00:34:13] There's just so much money that's shrouded in mystery.

[00:34:16] I like how Antonio Chacha puts it,

[00:34:18] where there's mystery, there's margin.

[00:34:20] Right, there's all of these numbers are hidden

[00:34:23] and they're laying there on the table

[00:34:24] and someone's picking it up.

[00:34:27] And if I can if I can toot my own horn for a moment, the fact that this would be able to be analyzed publicly by people like Antonio is the fact that the reason why we can do this is that the NAIDAC exists.

[00:34:46] And so that's why I take a lot of pride in my job is that we take information that otherwise would not exist to the public and we make it publicly available so that researchers and nerds and advocates

[00:34:52] can go out and actually piece this stuff together for themselves. So the fact that this whole system

[00:34:58] is paid for by the government and then all of the data is fully public. So anyone can use it

[00:35:04] for any reason.

[00:35:05] Just go to data.medicade.gov

[00:35:07] and it's available to anyone.

[00:35:09] There's incredible value in that system,

[00:35:12] taking information, which otherwise would be

[00:35:14] a proprietary trade secret

[00:35:16] and actually just making it public.

[00:35:17] Data.medicade.gov.

[00:35:20] Correct.

[00:35:20] Advice for plan sponsors is look at these

[00:35:23] NAIDAC prices because this will give you an

[00:35:25] indication of if you have a PBM as a vendor, this is an indication of how much that PBM

[00:35:30] might be pocketing and you can see that's the spreadsheet of all the NDCs which are the

[00:35:37] code, the numbers that represent each of the individual drugs.

[00:35:41] So go to data.medicade.gov and pull down that spreadsheet.

[00:35:47] It's free. It's put there for this reason is we want to provide more transparency to

[00:35:52] the drug supply chain. So that's why it's done. And we encourage everyone to use it as a public

[00:35:58] resource. Got it. Luke, is there anything else that you want to mention?

[00:36:01] I think we've covered a lot. There is one other thing I'd like to say. All of this dysfunction ends up causing downstream effects

[00:36:09] with respect to the working conditions

[00:36:11] for staff inside of pharmacies,

[00:36:14] as well as pharmacies closing

[00:36:17] and create this concept of pharmacy deserts,

[00:36:20] where there's neighborhoods or entire rural areas

[00:36:23] that don't have access to a pharmacy.

[00:36:25] All of this dysfunction doesn't solely just waste money for patients and plan sponsors.

[00:36:31] I mean, it would be bad enough if that were the case.

[00:36:35] But all of this wacky math that benefits wholesalers and PBMs often comes at the expense of pharmacies, and that results in less money to pay pharmacy

[00:36:48] staff. So in the chain pharmacies, you've seen walkouts recently that the staffing was

[00:36:54] just at such incredibly low levels that a lot of the chain pharmacies are just not functioning.

[00:37:00] And that's personal to me because I worked for Walgreens for 14 years. So I care about the concept of a chain function,

[00:37:06] chain pharmacy operating appropriately and delivering good customer service for

[00:37:10] their patients.

[00:37:11] And that's just not happening right now.

[00:37:13] And then also you have all these independent pharmacies just closing because

[00:37:17] this wacky math that we talked about is just incredibly damaging and it's not

[00:37:21] possible to run a business in this irrational environment

[00:37:25] for a lot of independent pharmacies. So that results in lack of patient access to pharmacies.

[00:37:29] I just want to draw that connection to know that this isn't just patients and health plan

[00:37:35] sponsors money being wasted. It also has this negative effect of making pharmacies just not

[00:37:42] function and or not exist. Luke Slindy, thank you so much for being on Real Atlas Health Value today.

[00:37:47] Thank you so much.

[00:37:48] So let's talk about going over to our website and typing your email address in the box to get

[00:37:53] the weekly email about the show that has come out. Sometimes people don't do that because they

[00:37:59] have subscribed on iTunes or Spotify and or were friends on LinkedIn. What you get in that email is a full and unredacted, unedited version of the whole introduction

[00:38:11] of the show transcribed.

[00:38:13] There's also show notes with timestamps, just a pricing you of the options that are available.

[00:38:18] Thanks so much for listening.

AWP,Formularies,NADAC,PBMs,Patient,Pharmacy,WAC,costs,drug,insurance,supply chain,myers and stauffer,

Recent Episodes

Pharma Rebates: A Few Nuances You May Not Have Thought Of, With Ann Lewandowski—Summer Shorts
June 19, 202519:2717.81 MB

Pharma Rebates: A Few Nuances You May Not Have Thought Of, With Ann Lewandowski—Summer Shorts

Listen On Your Favorite App So much can be said about pharma rebates or, as I’m starting to call them after speaking with my guest today, Ann Lewandowski, monies received back from manufacturers or even post-sale concessions. And we get a little bit into this today why rebates is just so much lingu...

EP479: What Could Go Wrong Covering High-Cost Claimants With Stop-Loss Reinsurance? With Andreas Mang and Jon Camire
June 12, 2025
479
27:2525.09 MB

EP479: What Could Go Wrong Covering High-Cost Claimants With Stop-Loss Reinsurance? With Andreas Mang and Jon Camire

Listen On Your Favorite App This show today, for sure, it’s for plan sponsors and anyone on or about plan sponsors; but also listen if you are serving high-cost claimants some other way. Because what you’ll learn here today is some insights relative to how plan sponsors go about making sure that th...

Take Two: EP433: The Mystery of the Weekly Claims Wire, With Justin Leader
June 05, 202538:4935.53 MB

Take Two: EP433: The Mystery of the Weekly Claims Wire, With Justin Leader

Listen On Your favorite App I decided to take a second listen to this episode due to the large number of posts on LinkedIn and conversations by the likes of Peter Hayes , Jamie Greenleaf , Steve Ditto , Julie Selesnick , Chris Deacon , Darren Fogarty just about the dollars disappearing when TPAs (t...

EP478: Stop-Loss Coverage, Part 1: How It Goes Right, and How It Can Go Horribly Wrong, With Andreas Mang and Jon Camire
May 29, 2025
478
31:5829.26 MB

EP478: Stop-Loss Coverage, Part 1: How It Goes Right, and How It Can Go Horribly Wrong, With Andreas Mang and Jon Camire

Listen On Your Favorite App Hey, question for you. Can it ever actually be better for a claim to get lasered? If your knee-jerk reaction is, “Nope. No, not so much. Lasered claims are always bad,” and/or if you have no idea what I’m talking about, do continue to listen. This question gets answered....

EP477: Through Line Show: What the Tribe Thinks You Need to Know About Trust or It’s Gonna Be a Problem. Also, Why You Are Smart, With Stacey Richter
May 22, 2025
477
18:3325.47 MB

EP477: Through Line Show: What the Tribe Thinks You Need to Know About Trust or It’s Gonna Be a Problem. Also, Why You Are Smart, With Stacey Richter

Listen On Your Favorite App A couple months ago, I did my very first episode ( EP467 ) that locked down a very clear through line, a theme tying together a bunch of RHV (Relentless Health Value) episodes from earlier this year. That earlier through line was a lack of good primary care means higher ...

Bonus Add-on to EP477: How to Earn Trust, With Charles Green
May 22, 202511:3310.57 MB

Bonus Add-on to EP477: How to Earn Trust, With Charles Green

Listen On Your Favorite App Welcome to this bonus add-on. I’m not gonna give much of an intro here except to say, we’ve come a long way, baby. And also, this short clip from the original show about trust is really a master class on what trust means and how to earn it. For a full transcript of this ...

EP476: Talking Whistleblowing and the Pharma Rebates Whistleblower Case With an Actual Whistleblower, With Ann Lewandowski
May 15, 2025
476
35:4732.75 MB

EP476: Talking Whistleblowing and the Pharma Rebates Whistleblower Case With an Actual Whistleblower, With Ann Lewandowski

Listen On Your Favorite App Alright, first off, let me calm down any attorneys right outta the gate here. We will not be talking about—at all—the legal activity that is currently ongoing that my guest today, Ann Lewandowski, is involved with. The suit mostly on our radar today is the one where an E...

Listen and Follow

Sponsored by Aventria Health Group
©2025 BD Bridges LLC. All Rights Reserved.